Discussion  by unknown
popliteal/tibial artery occlusive disease. Finally, an abnor-
mal SFA DUS can be used as an indirect marker to identify
more potentially at risk patients with CAD.
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DISCUSSION
Dr Zierler (Seattle, Wash). There has been a resurgence of
interest in vascular disease screening in recent years, particularly in
the areas of carotid disease, abdominal aortic aneurysms, and
peripheral arterial disease. As a past-president of the Intersocietal
Commission for the Accreditation of Vascular Laboratories, I
would encourage you to review the new standards for screening
that the ICAVL has developed, particularly if you already have an
accredited lab. With regard to the study that you just heard about,
I recognize that there is controversy over the merits of PAD
screening with respect to selection of patients, how the results
should be used, whether there is really any long-term benefit, and
so on, but I will focus my remarks today on the testing methods
used, because I think that is really where a lot of the interest lies.
Because of its simplicity and general availability, the ABI has
been the standard for PAD screening up to this point. However,
this paper introduces an alternative screening approach to PAD
based on duplex ultrasound of the superficial femoral artery, and it
describes a prospective study comparing it to the standard ABI.
The authors concluded that duplex ultrasoundwas amore sensitive
test than ABI and therefore was a better screening method for
PAD.
From my point of view, it is reassuring to have this shown in a
well-done prospective clinical study, but it is really not surprising at
all. After all, the ABI is an indirect test that assesses the distal effects
of arterial disease and allows us to make inferences about how
severe the lesions might be. It does not really allow us to detect the
early or minimal stages of atherosclerosis because a relatively large
burden of atherosclerosis is required to create a pressure gradient in
the leg and produce a positive test. So the ABI really should not be
a very good screening test for PAD, yet that is what we use. Duplex
scanning is a direct test that looks “directly” at the lesions of
interest. Therefore, it has the potential for detection of early or
minimal disease. This is analogous to the old OPG [oculoplethys-
mography] test vs duplex scanning for carotid disease, for those of
you who remember that test.
Since interpretation of the duplex ultrasound exams is a key
component of this study, I would like to raise some issues regard-
ing that aspect before I pose some specific questions. The manu-
script, and I think the presentation as well, described six categories
of ultrasound findings related to the SFA and these were based on
features such as intimal thickening, plaque, color changes, and so
on. For the purposes of this study, intimal thickening was a
negative test, but plaque without color change and less than 50%
stenosis were positive tests. The measurement of intimal-medial
thickness, or IMT, in the carotid artery has been established as a
tool for assessing cardiovascular risk and I see some parallels
between what was described in this study for the SFA and IMT in
the carotid artery. However, the classification scheme that was used
is a little bit vague. It is not quantitative the way IMT is, so I
wonder about the variability and reproducibility of some of the
results.
I have four questions. I usually advise discussants to limit
themselves to three questions, but I am going to ask four questions
because they are relatively brief. Number 1, color flow imaging is
subject to the same errors and artifacts as Doppler spectral analysis.
What can you tell us about standardization of your ultrasound
protocol with regard to instrument setup, color scale, Doppler
angle, and transducer selection—all the things that affect the way
the color flow image looks and therefore could affect your inter-
pretation?
Number 2, when does intimal thickening become plaque
without color change? This is not clear and obviously affects the
interpretation. With IMT you actually get a number, but your
interpretation appears to be more subjective than that.
Number 3, the variability of ABI measurements is well known.
I must have quoted Dr Dennis Baker’s old paper on this hundreds
of times in my career, but do you have any data on your variability
of duplex ultrasound interpretation? I realize that you do not have
a huge series, but maybe you have some impressions that you could
offer.
And, number 4, it appears that you examined the entire SFA
on both sides of these patients. It is well known that the earliest site
for atherosclerosis in the leg is the adductor canal segment of the
SFA. Can you tell us anything about the distribution of disease
along the SFA? Was it distal, was it mid, or was it proximal? Would
it be possible to limit a screening test to the distal SFA on one side
or the other side? Is there some way you could streamline this
exam? That would be interesting to know.
As a final thought, I think that duplex ultrasound should be a
better screening test for PAD than ABI, but I think the ABI still has
some advantages, particularly in the office setting, because it re-
quires suchminimal equipment, time, and effort. I compliment the
authors on this very interesting study and I appreciate the oppor-
tunity to discuss it.
Dr Ballard. Gene asked about the specifics of the ultrasound
study. We have Siemens Anteres ultrasound machines, which have
an arterial preset that we select to scan the vessels. Doppler angle is
always set to less than 60 degrees. The transducer is a VF94 linear
array and we use the same protocol for every patient. The two
technicians who were involved in this study are very experienced,
thus the protocol was well standardized.
When does intimal thickening become plaque? That is a very
good question, and in retrospect, it would have been instructive to
have quantified intimal thickening exactly by measuring IMT.
However, in this study, intimal thickening was diagnosed when the
usual thin white line of intima was raised more than 2 mm and
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when there was some acoustic shadowing associated with those
thickened areas. The reason that we did not select just intimal
thickening as an abnormal test result was because that criterion
alone makes ultrasound too sensitive to be useful as a screening
tool.
The variability of the ankle-brachial index is well known. I do
not have specific data on the variability of the ultrasound test but in
this particular study protocol, two experienced technicians per-
formed the examinations over and over again, which limited po-
tential variability.
Finally, you asked if we could shorten or limit the exam because
of the fact that superficial femoral artery disease begins at the adductor
hiatus. We assume this because SFA atherosclerotic disease appears in
this area per angiography that is performedwhen the patient becomes
symptomatic or has a significant drop in the ABI. Interestingly,
screening ultrasound detected more disease in the proximal aspect of
the superficial femoral artery just beyond the terminal common fem-
oral artery. So in fact, the adductor hiatus may not be the first place
that SFA disease starts. Based on our ultrasound findings, one could
potentially limit the study to the proximal half of the SFA if there was
a pressing need to shorten the exam.
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